within Pharmacolibrary.Drugs.S_SensoryOrgans.S01A_Antiinfectives.S01AA17_Erythromycin;

model Erythromycin
  extends Pharmacolibrary.Drugs.ATC.S.S01AA17;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01AA17</td></tr><td>route:</td><td>topical</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Erythromycin is a macrolide antibiotic used to treat a variety of bacterial infections. It is effective against many Gram-positive bacteria and some Gram-negative organisms. It is used in ophthalmic form (as referenced by ATC S01AA17) to treat eye infections such as conjunctivitis. Erythromycin remains approved and in clinical use today for both systemic and topical administration.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for topical ophthalmic administration assumed to be similar to systemic exposure, as no specific ocular PK studies available. Parameters based on published PK models of oral and IV erythromycin in healthy adults, used here as a rough estimate.</p><h4>References</h4><ol><li><p>Fitton, A, &amp; Goa, KL (1991). Azelaic acid. A review of its pharmacological properties and therapeutic efficacy in acne and hyperpigmentary skin disorders. <i>Drugs</i> 41(5) 780–798. DOI:<a href=\"https://doi.org/10.2165/00003495-199141050-00007\">10.2165/00003495-199141050-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1712709/\">https://pubmed.ncbi.nlm.nih.gov/1712709</a></p></li><li><p>Khan, S, et al., &amp; Jain, A (2018). Topical Delivery of Erythromycin Through Cubosomes for Acne. <i>Pharmaceutical nanotechnology</i> 6(1) 38–47. DOI:<a href=\"https://doi.org/10.2174/2211738506666180209100222\">10.2174/2211738506666180209100222</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29424323/\">https://pubmed.ncbi.nlm.nih.gov/29424323</a></p></li><li><p>Carls, A, et al., &amp; Mikus, G (2014). Systemic exposure of topical erythromycin in comparison to oral administration and the effect on cytochrome P450 3A4 activity. <i>British journal of clinical pharmacology</i> 78(6) 1433–1440. DOI:<a href=\"https://doi.org/10.1111/bcp.12497\">10.1111/bcp.12497</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25139487/\">https://pubmed.ncbi.nlm.nih.gov/25139487</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Erythromycin;
